switching glp 1 agonists New research from @doctorsigh shows that stopping GLP-1 medications doesn't Understanding GLP-1 receptor agonists and

The safety profile of retatrutide in individuals with T2DM was also favorable [103]

All GLP-1RAs [reviewed in (81)] and, more recently, the dual incretin receptor agonist tirzepatide, have been shown to lower postprandial triglyceride and ApoB-48 levels significantly (82)

doi: 10.3390/jcm10050985 174 UnniSWittbrodtEMaJSchauerhamerMHurdJRuiz-NegrnNet al

NCSL Resources on GLP-1 Drugs Prescription Drug Legislation Database Prescription Drug Policy Resource Center The Debate Over Weight-Loss Drugs Diabetes State Mandates and Insulin Copayment Caps The average annual list price of GLP-1s is $12,000 and, according to a Peterson-KFF tracker, most large employer health plans restrict coverage for weight loss

Liu Z-Z, Duan X-X, Yuan M-C, Yu J, Hu X, Han X, et al

421,422 Remarkably, GLP-1R activation in certain nuclei (such as the VTA, NAc, and vHP) elicits reductions in food intake and body weight without concurrent nausea responses